← Eichor
Study identifier: NCT06499051 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Epidemiology of French Sexual Offenders. A Cross-sectional Study

Condition: Psychiatric Disorder  ·  Sponsor: Hôpital le Vinatier

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The epidemiology of sexual offenders has been poorly studied in the literature. A retrospective and prospective study will allow for the examination of the clinical profile of sexual offense perpetrators, risk and recurrence factors, as well as psychiatric or medical treatment. Since 2015, the Auvergne-Rhône-Alpes region has 8 reference platforms for sexual offense perpetrators, offering personalized assessment according to criteria defined by the Regional Health Agency (ARS). After this assessment, a multidisciplinary meeting is organized to define a tailored care plan. This study, called ARAVS (Auvergne Rhone-Alpes Sexual Offenders), aims to conduct an epidemiological, clinical, and socio-demographic study of patients in these platforms.

This description comes directly from the study's public registry record.

Talk to the study team

Sabine Mouchet, Dr  ·  +33 4 37 91 53 09  ·  sabine.mouchet@ch-le-vinatier.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CRIAVS - Centre Hospitalier Le VinatierBron, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06499051